Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Camille L. Bedrosian Sells 12,425 Shares

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Camille L. Bedrosian sold 12,425 shares of the company’s stock in a transaction on Monday, March 31st. The stock was sold at an average price of $3.47, for a total value of $43,114.75. Following the sale, the insider now owns 194,375 shares of the company’s stock, valued at $674,481.25. This trade represents a 6.01 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX stock opened at $3.78 on Thursday. The company has a market cap of $334.92 million, a price-to-earnings ratio of -0.99 and a beta of -0.51. The stock’s fifty day moving average price is $3.55 and its 200 day moving average price is $4.05. Amylyx Pharmaceuticals, Inc. has a 1-year low of $1.58 and a 1-year high of $7.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The company had revenue of ($0.67) million for the quarter. As a group, equities research analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Blue Trust Inc. lifted its position in Amylyx Pharmaceuticals by 232.1% during the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock worth $26,000 after acquiring an additional 4,883 shares during the period. Fox Run Management L.L.C. purchased a new position in shares of Amylyx Pharmaceuticals in the fourth quarter worth about $45,000. Alpine Global Management LLC acquired a new stake in shares of Amylyx Pharmaceuticals during the fourth quarter worth about $45,000. RPO LLC purchased a new stake in Amylyx Pharmaceuticals in the fourth quarter valued at approximately $46,000. Finally, EntryPoint Capital LLC acquired a new position in Amylyx Pharmaceuticals in the 4th quarter worth approximately $53,000. 95.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Amylyx Pharmaceuticals in a research report on Wednesday, March 5th. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.33.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.